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 BRIEF COMMUNICATION 
with a 3 × 2 factorial design consisting of 
three aspirin groups (placebo, 81, and 325 
mg/d) and two folic acid groups (placebo 
and 1 mg/d) (clinicaltrials.gov identifi er: 
NCT00272324). At recruitment, patients 
completed a questionnaire regarding their 
personal characteristics, medical history, 
and lifestyle habits. Adenoma recurrence was 
determined by colonoscopy and pathology 
review 3 years later, and at that time, aspi-
rin treatment was terminated. Participants 
were invited to continue their blinded folic 
acid assignment until their next colonos-
copy, which was performed about 3 – 5 years 
after the year 3 examination. All patients 
provided written informed consent, and 
institutional review board approval was 
obtained at each participating clinical center. 
The trial found that subjects treated with 81 
mg of aspirin, but not 325 mg of aspirin, had 
statistically signifi cantly reduced risk for 
recurrent adenomas ( 2 ). By contrast, folic 
acid supplementation was associated with an 
increased risk of advanced lesions (tubulovil-
lous, villous, or large adenomas; high-grade 
dysplasia; or invasive cancer) ( 8 ). 
 The present analysis examined data 
from randomization through the year 3 
 Both observational studies and clinical tri-
als have demonstrated consistently the effi-
cacy of low-dose aspirin ( ≤ 325 mg/d) in the 
chemoprevention of colorectal adenomas 
( 1 – 4 ), but the antineoplastic mechanisms of 
low-dose aspirin are not known. Because 
inflammation is thought to be involved in 
the etiology of colorectal neoplasia ( 5 – 7 ), 
we hypothesized that low-dose aspirin could 
change the circulating levels of inflamma-
tory cytokines and thereby reduce risk of 
colorectal neoplasms. 
 We conducted secondary analyses in the 
Aspirin/Folate Polyp Prevention Study 
( 2 , 8 ), a clinical trial of aspirin and/or folic 
acid for the prevention of recurrence of 
colorectal adenomas, to examine several 
hypotheses. First, we evaluated the effects 
of daily low-dose aspirin and folic acid on 
circulating levels of proinfl ammatory mark-
ers, namely C-reactive protein (CRP), inter-
leukin 6 (IL-6), and tumor necrosis factor   
(TNF-  ), and on anti-infl ammatory cytokine 
receptors, including soluble TNF receptor 
type II (sTNF-R2) and IL-1 receptor 
antagonist (IL-1Ra). Although IL-6 and 
TNF-  may have growth-promoting and 
oncogenic bioactivities as indicated in labo-
ratory studies ( 9 – 11 ), the soluble receptors 
sTNF-R2 and IL-1Ra block binding of TNF 
and IL-1, respectively, to their cell-surface 
receptors, resulting in potent inhibition of 
the activities of these proinfl ammatory 
cytokines ( 12 , 13 ). Therefore, our second 
objective was to assess whether changes in 
these infl ammation markers affected risk of 
recurrent adenomas. Finally, we examined 
if the previously observed treatment effects 
of aspirin and folic acid on adenoma recur-
rence were mediated by these infl ammation 
markers. 
 In the double-blind randomized Aspirin/
Folate Polyp Prevention Study ( 2 , 8 ), 
patients with a recent history of colorectal 
adenomas were recruited between July 6, 
1994, and March 20, 1998, into the trial 
 Antagonistic Effects of Aspirin and 
Folic Acid on Inflammation Markers and 
Subsequent Risk of Recurrent Colorectal 
Adenomas 
 Gloria Y. F.  Ho ,  Xiaonan  Xue ,  Mary  Cushman ,  Gail  McKeown-Eyssen ,  
 Robert S.  Sandler ,  Dennis J.  Ahnen ,  Elizabeth L.  Barry ,  Fred  Saibil ,  
 Robert S.  Bresalier ,  Thomas E.  Rohan ,  John A.  Baron 
 The Aspirin/Folate Polyp Prevention Trial found that aspirin, but not folic acid, 
reduced recurrence of colorectal adenomas. This study examined whether treat-
ment effects on inflammation markers explained the trial results. The trial had a 
factorial design with three aspirin (placebo, 81, and 325 mg/d) and two folic acid 
(placebo and 1 mg/d) groups. There were 884 subjects who had colonoscopic evalu-
ation for adenomas at year 3 and plasma levels of C-reactive protein (CRP), interleu-
kin 6 (IL-6), tumor necrosis factor   (TNF-  ), soluble TNF receptor type II (sTNF-R2), 
and IL-1 receptor antagonist (IL-1Ra) measured at baseline and year 3. Among indi-
viduals not receiving folic acid, there was a 4% decrease (mean ratio of year 3 to 
baseline levels = 0.96, 95% confidence interval [CI] = 0.82 to 1.14) in CRP for a period 
of 3 years in the 325 mg of aspirin group vs a 20% increase (mean ratio = 1.20, 95% 
CI = 1.03 to 1.41) in the placebo group ( P = .027). By contrast, the reverse was 
observed among individuals who also received folic acid ( P 
interaction
 = .013). Changes 
in inflammation markers were not associated with adenoma recurrence. Low-dose 
aspirin (325 mg/d) is beneficial in stabilizing CRP levels, which may be abrogated by 
folate. Nevertheless, inflammation markers do not mediate the chemopreventive 
effect of aspirin on colorectal adenomas. 
 J Natl Cancer Inst 2009;101:1650–1654 
 Affiliations of authors: Department of Epidemiology 
& Population Health, Albert Einstein College of 
Medicine, Bronx, NY (GYFH, XX, TER); Department 
of Medicine and Department of Pathology, The 
University of Vermont, Burlington, VT (MC); 
Department of Public Health Sciences and 
Department of Nutritional Sciences (GM-E) and 
Division of Gastroenterology, Department of 
Medicine (FS), University of Toronto, Toronto, 
ON, Canada; Division of Gastroenterology and 
Hepatology, Department of Medicine, University 
of North Carolina, Chapel Hill, NC (RSS); 
Department of Medicine, Denver Department of 
Veterans Affairs Medical Center and Department 
of Medicine, University of Colorado Denver School 
of Medicine, Denver, CO (DJA); Department of 
Community and Family Medicine (ELB) and 
Department of Medicine (JAB), Dartmouth 
Medical School, Hanover, NH; Department of 
Gastrointestinal Medicine and Nutrition, MD 
Anderson Cancer Center, Houston, TX (RSB) . 
 Correspondence to: Gloria Y. F. Ho, PhD, 
Department of Epidemiology & Population Health, 
Albert Einstein College of Medicine, Bronx, NY 
10461 (e-mail:  gloria.ho@einstein.yu.edu ). 
 See “Funding” and “Notes” following “References.” 
 DOI: 10.1093/jnci/djp346 
 © The Author 2009. Published by Oxford University 
Press. All rights reserved. For Permissions, please 
e-mail: journals.permissions@oxfordjournals.org. 
 Advance Access publication on October 12, 2009. 
jnci.oxfordjournals.org   JNCI | Brief Communication 1651
colonoscopy; it included 884 participants 
who had nonfasting blood samples col-
lected at both baseline and year 3 visits 
( Figure 1 ). These 884 participants were 
similar to those who were excluded from 
the analysis with respect to demographic 
and medical characteristics. Their paired 
plasma samples, which were stored at 
  70°C, were assayed simultaneously for 
infl ammation markers by the following 
methods: CRP by latex-enhanced immu-
nonephelometry (interassay correlation of 
variation = 4%; Behring Diagnostics, San 
Jose, CA), IL-6 by an ultrasensitive solid-
phase enzyme-linked immunosorbent assay 
(interassay correlation of variation = 14%; 
R&D Systems, Minneapolis, MN), TNF-  
and IL-1Ra together by a multiplex assay 
(interassay correlation of variations of 13% 
and 13%, respectively; Human Cytokine/
Chemokine panel; Millipore, Billerica, 
MA), and sTNF-R2 by another multiplex 
assay (interassay correlation of variation  = 
9%; Death Receptor Kit; BioSource 
International, Camarillo, CA). 
 To determine the effects of aspirin and 
folic acid treatments on infl ammation 
markers, levels of infl ammation markers 
were fi rst natural log transformed to 
improve normality and change in an infl am-
mation marker (  ) was calculated as [ln 
(year 3 level)   ln (baseline level)]. In linear 
regression analysis,   of each infl ammation 
marker (dependent variable) was regressed 
against the main effects of aspirin (3 groups) 
and folic acid (2 groups) randomizations as 
well as the interaction between aspirin and 
folic acid with adjustment for covariates 
that were associated with that particular 
infl ammation marker. The adjusted mean 
of   for each treatment group was obtained 
from the regression model, and the geo-
metric mean of   was equivalent to the 
mean ratio of year 3 to baseline marker 
levels. To examine whether changes in 
infl ammation markers were associated with 
risk of recurrent adenomas, the two out-
come variables, any adenoma and advanced 
adenomas at year 3, were analyzed by log-
linked binomial regression models. Change 
in each infl ammation marker was analyzed 
as an independent variable with adjustment 
for infl ammation marker level at baseline 
and established risk factors for colorectal 
adenomas. To evaluate whether changes in 
infl ammation markers might mediate the 
effects of aspirin and folic acid treatments 
 CONTEXT AND CAVEATS 
 Prior knowledge 
 In the Aspirin/Folate Polyp Prevention Trial, 
aspirin, but not folic acid, reduced the 
recurrence of colorectal adenomas. 
 Study design 
 Secondary analysis of the Aspirin/Folate 
Polyp Prevention Trial that examined 
changes in plasma levels of inflammation 
markers C-reactive protein (CRP), soluble 
TNF receptor type II (sTNF-R2), interleukin 6 
(IL-6), tumor necrosis factor   (TNF-  ), and 
IL-1 receptor antagonist (IL-1Ra) at baseline 
and at year 3 of 884 subjects. The trial had 
three aspirin groups (placebo at 81 and 325 
mg/d) and two folic acid groups (placebo 
and 1 mg/d). 
 Contributions 
 For subjects who did not receive folic acid, 
CRP levels in those in the 325 mg/d aspirin 
group changed very little, whereas it was 
statistically significantly increased (by 20%) 
in the placebo group. For subjects who 
received folic acid, the reverse association 
was observed. Changes in levels of inflam-
mation markers were not associated with 
adenoma recurrence. 
 Implications 
 Low-dose aspirin may reduce CRP levels, 
and aspirin in combination with folate may 
have an opposite effect; however, the mark-
ers of inflammation tested in this analysis 
are likely not involved in the chemopreven-
tive effect of aspirin on colorectal adenomas 
that was previously observed. 
 Limitations 
 Plasma levels rather than tissue levels of 
the inflammation markers were measured. 
 From the Editors 
on recurrence of adenomas, we examined 
relative risks for the associations of aspirin 
and folic acid treatments with recurrence of 
adenomas while controlling for established 
adenoma risk factors from two log-linked 
binomial regression models: 1) with change 
in infl ammation marker (ie, the potential 
mediator) entered into the model and 2) 
without such an adjustment. Attenuated 
relative risks from the former model, as 
compared with the latter, would suggest 
that treatment effects might be partially 
mediated by the infl ammation marker that 
was entered in the model. All statistical 
tests were two-sided, and differences for 
which  P values were less than .05 were con-
sidered statistically signifi cant. 
 The average age of patients was 57 (±9) 
years, 86% were whites, and 64% were 
males. There were no important differences 
in baseline characteristics, including the 
levels of infl ammation markers, among the 
six randomization groups. Among individu-
als who did not receive folic acid, those who 
took 325 mg of aspirin had stable levels of 
proinfl ammatory markers, particularly 
CRP, for a period of 3 years ( Figure 2 ). 
There was a negligible 4% decrease (mean 
ratio of year 3 to baseline levels = 0.96, 95% 
confi dence interval [CI] = 0.82 to 1.14) in 
CRP levels at year 3 in the 325 mg of aspi-
rin group as compared with a 20% increase 
(mean ratio = 1.20, 95% CI = 1.03 to 1.41) 
in the placebo group ( P = .027 comparing 
the two groups). However, among individ-
uals who also received folic acid, the reverse 
trend was observed. For example, TNF-  
levels at year 3 increased by 39% (mean 
ratio = 1.39, 95% CI = 1.09 to 1.77) among 
subjects taking 325 mg of aspirin, whereas 
the placebo group had virtually no change 
(mean ratio = 0.98, 95% CI = 0.76 to 1.26) 
in their TNF-  levels ( P = .023 comparing 
the two groups). The antagonistic interaction 
between folic acid and 325 mg of aspirin 
was statistically signifi cant for CRP ( P = .013) 
and TNF-  ( P = .038) and was not for IL-6 
( P = .063). Folic acid given alone as well 
as 81 mg of aspirin, given with or without 
folic acid, had no effect on plasma levels 
of CRP, TNF-  , and IL-6. Treatments 
had no effect on the levels of sTNF-R2 or 
IL-1Ra (data not shown). 
 Changes in plasma levels of CRP, 
TNF-  , and IL-6 were further assessed for 
their clinical signifi cance; none was asso-
ciated with risk of adenoma recurrence 
( Table 1 ). Hence, it became unlikely that 
these markers of infl ammation could medi-
ate the effects of aspirin and folic acid. 
Indeed, when the relative risks for associa-
tions of treatment groups with adenoma risk 
after accounting for change in CRP, TNF-  , 
or IL-6 were compared with those without 
such an adjustment, the former relative risks 
were attenuated by less than 5%, suggesting 
that treatment effects were not explained by 
these infl ammation markers. As for 
sTNF-R2 or IL-1Ra, neither their baseline 
levels nor 3-year changes were related to 
recurrent adenomas (data not shown). 
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 Figure 1 .  Design of the trial and fl ow of 
participants. 
 It is known that a high dose of aspirin 
(>3 g/d) is required to achieve its clinical 
anti-infl ammatory effects ( 14 ). However, it 
is unclear whether low-dose aspirin (81 –
 325 mg/d) has a modest anti-infl ammatory 
effect, particularly on lowering the levels 
of proinfl ammatory cytokines, because 
previous clinical trials had small sample 
sizes and treatment periods of less than 2 
months ( 15 – 18 ). Our study demonstrated 
that in the absence of folic acid treatment, 
long-term intake of 325 mg of aspirin daily 
precluded CRP plasma concentrations 
from escalating over time. However, sub-
jects who did not receive any treatment 
(double-placebo) had elevated levels for a 
3-year period. It has also been shown in 
the general population that CRP increases 
with age ( 19 ). Our data suggest that 325 mg 
of aspirin stabilizes the levels of CRP. 
Higher doses may be necessary to further 
reduce the levels of proinfl ammatory 
markers. 
 In our study, the levels of infl ammation 
markers for a period of 3 years among sub-
jects who received 1 mg of folic acid alone 
were not statistically signifi cantly different 
from those in the double-placebo group. 
Our data and the majority of previous stud-
ies ( 20 – 25 ) do not support an important 
anti-infl ammatory role of folate in modu-
lating infl ammatory cytokines. 
 The antagonistic interaction between 
325 mg of aspirin and folic acid, such that 
the two regimens together increase the 
levels of proinfl ammatory markers, needs 
to be confi rmed in future studies. The bio-
logical mechanism for such an interaction 
is unknown. A few studies ( 26 – 28 ) have 
reported that high doses of aspirin have 
antifolate effects, which may be crucial for 
the anti-infl ammatory action. If so, one can 
speculate that low-dose aspirin in the pres-
ence of high folic acid levels from supple-
mentation may not yield the antifolate 
activity needed to have an effect on infl am-
matory cytokines. Nevertheless, our study 
highlights the potential complexity of com-
bining the two regimens for primary or 
secondary disease prevention. 
 Changes in levels of CRP, IL-6, and 
TNF-  in the 3-year period had trivial 
clinical signifi cance. These changes were 
not associated with the risk of recurrent 
adenomas nor did they mediate the effects 
of aspirin and folic acid on risk of ade-
nomas. It has been shown that infl amma-
tory responses and cytokine signaling in 
intestinal epithelial cells may be responsible 
for the pathogenesis of chronic intestinal 
disorders ( 29 ). Therefore, the lack of asso-
ciations of recurrent adenoma risk with 
proinfl ammatory and anti-infl ammatory 
 Figure 2 .  Adjusted mean ratios of year 3 to baseline infl ammation marker 
levels by randomization group among 884 subjects in this study.  A) CRP 
= C-reactive protein.  B) TNF-  = tumor necrosis factor   .  C) IL-6 = inter-
leukin 6. Without folic acid supplemention ( triangles ). With 1 mg of folic 
acid ( squares ). For each infl ammation marker, adjusted means of   , 
defi ned as [ln (year 3 level)   ln (baseline level)], for the six treatment 
groups were obtained from a linear regression model. The geometric 
mean of   , which was equivalent to the ratio of year 3 to baseline marker 
levels, is presented. The basic regression model included the following 
covariates: aspirin assignment, folic acid assignment, interaction of 
aspirin and folic acid, sex, race (white vs other), baseline infl ammation 
marker level (continuous), age (continuous), body mass index (continu-
ous), and smoking status (current vs ever or never). Each infl ammation 
marker was analyzed using the basic model with additional covariates 
that were associated with that particular marker. CRP: history of colorec-
tal cancer or adenomas in fi rst-degree relatives, number of pregnancies 
(continuous), and number of years using oral contraceptive pills (con-
tinuous). TNF-  : history of colorectal cancer or adenomas in fi rst-degree 
relatives. IL-6: use of nonsteroidal anti-infl ammatory drugs and calcium 
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markers in our study could be because of 
the fact that plasma instead of tissue levels 
of infl ammation markers were measured. It 
is also possible that infl ammation markers 
are associated with the initial development 
of colorectal adenomas but not with 
recurrence. 
 In summary, our data suggest that low-
dose aspirin has modest effects on stabiliz-
ing CRP, which may be abrogated by a high 
level of folate. However, such benefi cial 
effects do not appear to confer protection 
against colorectal neoplasia. Infl ammation 
markers do not mediate the previously 
observed effects of aspirin and folic acid on 
colorectal adenomas. 
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